Subscribe to Print Edition | Sat., July 19, 2008 Tamuz 16, 5768 | | Israel Time: 14:14 (EST+7) web haaretz.com   Back to Homepage Rosner's Domain Diplomacy Defense Jewish World Opinion National Print Edition Car Rental Books Haaretz Magazine Business Real Estate Easy Start Travel Week's End Anglo File

Last update - 08:00 19/07/2008 Teva to buy U.S. drug giant for $7.5B in biggest ever purchase by Israeli company By Yoram Gabison, TheMarker Correspondent, and The Associated Press Tags: Barr, Teva Teva Pharmaceuticals officially announced on Friday its plan to purchase U.S. generic drugmaker Barr Pharmaceuticals for $7.5 billion. If completed it would be the biggest deal ever by an Israeli company. The price is 44% above Barr's market value. Teva Pharmaceutical Industries Ltd. also is offering to assume $1.5 billion of Montvale, New Jersey-based Barr Pharmaceuticals Inc.'s debt. Barr shareholders will receive $39.90 in cash and 0.6272 of a Teva American Depositary Receipt for each share they own, or a total purchase price of $66.50 per share. That represents a 16 percent premium to Barr's $57.17 closing price Thursday. Advertisement Barr shares finished at $46.82 Wednesday, before reports that a deal was in the works sent the stock climbing 22 percent. Already the largest generic drug maker in the world, Teva reported $9.4 billion in sales in 2007. Barr posted $2.5 billion in revenue, and the company describes itself as the largest maker of oral contraceptives in the U.S. It began selling a generic version of Bayer AG's birth-control pill Yasmin in the U.S. in July. Barr also has the rights to sell a generic version of the attention deficit hyperactivity disorder drug Adderall XR starting April 1, 2009. The deal will give Teva a larger presence in Central and Eastern Europe, where Barr already has a footprint because of its 2006 purchase of Pliva, a Croatian drug maker. Based on Barr's 108.1 million shares outstanding at April 28, the deal is valued at $7.19 billion before assumed debt. In a statement, the companies valued the deal at $7.46 billion before debt. Teva CEO Shlomo Yannai declared six months ago that Teva would increase its U.S. market share from 20% to 30% by 2012. The greatest advantage for Teva of the deal, which was first revealed on Wednesday on the Web site of TheMarker, would be in increasing its lead over Sandoz. Teva is the world's largest generic drug manufacturer. Sandoz, the generic subsidiary of Novartis, is number two. Barr's product line of branded drugs would give Teva a much greater presence in Eastern and Central Europe. Its ethical drug lines from its Duramed subsidiary would also add to Teva's share of the birth control market. Barr has a big advantage over Teva there, with such drugs as its Seasonique contraceptive pill and the morning-after pill Plan B. Altogether Barr sells 25 different types of oral contraceptives. Barr's Enjuvia hormonal treatment for menopause would also be a nice addition to the Teva medicine chest. Another benefit for Teva is Barr's access to the Russian market as well as to Poland and to Croatia, where Barr has a 37% market share. Barr purchased its Croatian subsidiary, PLIVA, in October 2006 for $2.5 billion. That company operates throughout Eastern and Central Europe. Barr's chairman and CEO is Bruce Downey. Barr Pharmaceuticals is actually a holding company, operating through subsidiaries such as Barr Laboratories, Duramed and PLIVA. Barr's present market value is $5.2 billion. It sells in 30 countries and develops both ethical and generic drugs. It had net profits of $23 million on sales of $608 million in the first quarter of 2008, up from profits of $12 million and sales of $597 million in the previous quarter, the last of 2007. Its EBITDA - earnings before interest, taxes, depreciation and amortization - for the first quarter of the year was $153 million. It has 8,900 employees around the globe. The headquarters of the holding company is in New York, and Barr Labs is located in New Jersey. Despite its strength in Central and Eastern Europe, its sales are still concentrated in the U.S., with 71% of its sales there. In terms of the product mix, birth control pills made up 31% of revenues, while anti-psychotic drugs brought in 11% of sales with an additional 11% coming from pharmaceutical therapies for cardiac disease. Ethical drugs made up 19% of Barr's sales, though the gross profit margins on those drugs reached 68%. Barr was trading at a price to earnings ratio of 16.9, which means the sale price would reflect a P/E ratio of 24. Teva is expected to pay for the deal with a mixture of shares and cash, as it did in the Ivax merger in 2006. Teva sells 331 generic drugs in the U.S. and Barr would add another 150, compared to a total of 200 sold by Sandoz. Number three is Mylan, with a list of 170 drugs, followed by Barr in fourth place. As of the end of the first quarter of 2008, Barr was waiting for approval of an additional 70 generic drugs with a combined existing market worth $30 billion in sales a year. An ongoing romance All told, the purchase would make it much easier for Teva to meet its 2009 goals. Barr also develops bio-generic drugs, a market that is expected to grow strongly in coming years as patents expire. Barr also manufacturers injected drugs, a field Teva moved into in 2003 with its purchase of Sicor. Teva and Barr have been cooperating since September 2005, when they signed an agreement to market Fexofenaine, a generic version of Allegra-D for the treatment of seasonal allergies and chronic skin diseases. The two have also cooperated on other generic drugs. The joint projects with Teva have given both companies a good chance to appreciate each other's strengths and opportunities and has made it natural for Teva to think about the next step Bookmark to del.icio.us   Farewell ambassador Even the Arab envoys came to say goodbyeto Israel's UN ambassador Dan Gillerman. A tale of two mothers Israeli documentary 'To Die in Jerusalem' earns three Emmy nominations.   1.   Teva-Barr 17:37  |  yigal koltin 18/07/08   2.   Hyenas 10:21  |  Clickfool 19/07/08

Read & React Samir Kuntar: I'm yearning more than ever to confront Israel Responses: 276 Shalit talks hit impasse as Hamas hangs on to 'asset' Responses: 146 Marco Greenberg: The real story of anti-Semitism in the U.S. Responses: 166 ANALYSIS / What does Nasrallah mean by 'defense strategy'? Responses: 103 David Landau: Olmert has walked right into Nasrallah's trap Responses: 45 Rosner's Domain What will Obama look for in Jerusalem (and Ramallah)? Is there a crisis in U.S.-Lebanon relations? (WTR) Do U.S. Jews really support 'necessary compromises' for peace? Why does Israel keep agreeing to prisoner swaps? More Headlines 11:43 IDF says troops shoot and kill Syrian drug smuggler 13:08 Hezbollah vows to carry out more abductions of IDF troops 11:55 Report: Obama's planned visit to Mideast raises serious security concerns 07:22 VIDEO: What Talansky said about Olmert in his testimony 12:05 British prime minister holds talks with Iraqi leaders in Baghdad 07:50 Spat between Jews and Muslims sours Saudi interfaith summit 07:35 This hyphenated life, post two / Jew me down 07:26 Israeli film on mothers of suicide bomber, victim tapped for 3 Emmys 12:25 Fatah policeman killed by Hamas gunmen in Gaza Strip 21:59 Six arrested in Israel for allegedly plotting attack on Bush 08:36 Shalit talks deadlocked as Hamas hangs on to 'asset' 08:00 Teva to buy U.S. drug giant for $7.5B in biggest ever purchase by Israeli company 05:55 ANALYSIS / What does Nasrallah mean by 'defense strategy'? 07:25 Rabbis felt emotional difficulty in identifying remains Previous Editions Select Day 18 jul 17 jul 16 jul 15 jul 14 jul 13 jul 11 jul 10 jul 09 jul 08 jul 07 jul 06 jul

Special Offers Advertisement Fattal Hotel Chain Perfectly located hotels on best resorts of Israel. Israel's Premier Real Estate Website www. israel-property.com Dan Hotels Israel Live the Legend & experience an Unforgettable Summer Vacation Yossi Avrahami Presents: New Luxurious Projects in North Tel Aviv & Eilat Holyland Park Jerusalem Apartment Tower World Class Luxury Your vacation starts here Israel Travel Center Guaranteed Lowest Rates Hebrew Summer courses From $39.95 ISRAEL BONDS Build Israel Israel bonds - a multi-purpose way to celebrate Israel's 60th Eldan Rent a Car Israel's leading car rental company offers you a 20% discount on all online reservations Junkyard Junk a car - get free towing nationwide and a tax-deductible receipt

Home | TV | Print Edition | Diplomacy | Opinion | Arts & Leisure | Sports | Jewish World | Underground | Site rules |

Real Estate in Israel | Travel to Israel with Haaretz | Hotels Israel | Restaurants Israel | Tourist attractions Israel | Shops Israel

birthright Israel | Search engine marketing

Haaretz.com, the online edition of Haaretz Newspaper in Israel, offers real-time breaking news, opinions and analysis from Israel and the Middle East. Haaretz.com provides extensive and in-depth coverage of Israel, the Jewish World and the Middle East, including defense, diplomacy, the Arab-Israeli conflict, the peace process, Israeli politics, Jerusalem affairs, international relations, Iran, Iraq, Syria, Lebanon, the Palestinian Authority, the West Bank and the Gaza Strip, the Israeli business world and Jewish life in Israel and the Diaspora.

© Copyright  Haaretz. All rights reserved